These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33027640)

  • 1. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome.
    Pinto B; Morelli G; Rastogi M; Savardi A; Fumagalli A; Petretto A; Bartolucci M; Varea E; Catelani T; Contestabile A; Perlini LE; Cancedda L
    Neuron; 2020 Dec; 108(5):887-904.e12. PubMed ID: 33027640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome.
    Moreau M; Dard R; Madani A; Kandiah J; Kassis N; Ziga J; Castiglione H; Day S; Bourgeois T; Matrot B; Vialard F; Janel N
    Cell Mol Life Sci; 2024 May; 81(1):215. PubMed ID: 38739166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome.
    Aziz NM; Guedj F; Pennings JLA; Olmos-Serrano JL; Siegel A; Haydar TF; Bianchi DW
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29716957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
    Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
    Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice.
    Rueda N; Vidal V; García-Cerro S; Narcís JO; Llorens-Martín M; Corrales A; Lantigua S; Iglesias M; Merino J; Merino R; Martínez-Cué C
    Brain Behav Immun; 2018 Oct; 73():235-251. PubMed ID: 29758264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus.
    Rice RA; Spangenberg EE; Yamate-Morgan H; Lee RJ; Arora RP; Hernandez MX; Tenner AJ; West BL; Green KN
    J Neurosci; 2015 Jul; 35(27):9977-89. PubMed ID: 26156998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreasing the Expression of GABA
    Vidal V; García-Cerro S; Martínez P; Corrales A; Lantigua S; Vidal R; Rueda N; Ozmen L; Hernández MC; Martínez-Cué C
    Mol Neurobiol; 2018 Jun; 55(6):4745-4762. PubMed ID: 28717969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
    Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
    Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Uguagliati B; Bonasoni MP; Bartesaghi R; Guidi S
    Brain Pathol; 2019 May; 29(3):366-379. PubMed ID: 30325080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome.
    Uguagliati B; Al-Absi AR; Stagni F; Emili M; Giacomini A; Guidi S; Nyengaard JR; Bartesaghi R
    Hippocampus; 2021 Apr; 31(4):435-447. PubMed ID: 33464704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
    Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
    Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forebrain Shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of Down syndrome and its euploid littermates.
    Gao FJ; Klinedinst D; Fernandez FX; Cheng B; Savonenko A; Devenney B; Li Y; Wu D; Pomper MG; Reeves RH
    Acta Neuropathol Commun; 2021 Aug; 9(1):137. PubMed ID: 34399854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
    Emili M; Stagni F; Salvalai ME; Uguagliati B; Giacomini A; Albac C; Potier MC; Grilli M; Bartesaghi R; Guidi S
    Neurobiol Dis; 2020 Jul; 140():104874. PubMed ID: 32325119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
    Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
    Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice.
    Seo H; Isacson O
    Exp Neurol; 2005 Jun; 193(2):469-80. PubMed ID: 15869949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome.
    Day SM; Yang W; Wang X; Stern JE; Zhou X; Macauley SL; Ma T
    eNeuro; 2019; 6(2):. PubMed ID: 31040160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.